Abstract: The present invention provides a novel liposome composition containing eribulin or its pharmacologically permissible salt, and its method of manufacture.
Abstract: Described herein are compositions and methods for improving homology directed repair (HDR) efficiency and reducing homology-independent integration following introduction of double strand breaks with engineered nucleases. Additionally, modifications to double stranded DNA donors to improve the donor potency and efficiency of homology directed repair following introduction of double stranded breaks with programmable nucleases.
Type:
Grant
Filed:
October 23, 2020
Date of Patent:
July 16, 2024
Assignee:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Jessica Woodley, Bernice Thommandru, Joseph Dobosy, Mark Behlke, Adam Clore, Garrett Rettig, Beimeng Sun
Abstract: Compounds that either produce a higher proportion or greater absolute number of phenotypically identified naive, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies, such as those providing improvements in one or more therapeutic outcomes, are provided.
Type:
Grant
Filed:
July 19, 2018
Date of Patent:
July 16, 2024
Assignees:
FATE THERAPEUTICS, INC., JUNO THERAPEUTICS, INC.
Inventors:
Jonathan Rosen, Eigen Peralta, Ian Hardy, Betsy D. Rezner, Christian Maine, Daniel Shoemaker, David Robbins, Lucas Thompson
Abstract: Described herein are organoids that include at least one type of immune cell along with systems and devices including the same. Methods of preparing and using such organoids, devices and systems are also described herein.
Type:
Grant
Filed:
February 1, 2019
Date of Patent:
July 16, 2024
Assignee:
WAKE FOREST UNIVERSITY HEALTH SCIENCES
Inventors:
Aleksander Skardal, Konstantinos Votanopoulos
Abstract: A solution is described for preserving cells and/or extra-cellular components in naturally expressed bodily fluids (e.g. saliva, sputum, urine) for further downstream analysis and/or for diagnosis of a medical condition. The solution may be hypertonic with respect to blood. Techniques are described for enriching cells from a sample of a naturally expressed bodily fluid, and/or for analysis, e.g. to diagnose medical conditions such as cancer, obesity, infections, autism, Alzheimer disease, hetotological disorders, cardiovascular disease or disorders, diabetes, vulnerable plack, LTBI, HIV infection, COPD, ACQS.
Type:
Grant
Filed:
February 9, 2016
Date of Patent:
July 16, 2024
Assignee:
DNA Genotek, INC.
Inventors:
Stephen Andrews, Youssef Biadillah, Manasi Jain, David S. Frank, John R Zeman, Charles T. Tackney
Abstract: The invention relates to a recombinant adeno-associated virus (AAV) capsid protein, which is a hybrid between AAV serotype 9 (AAV9) and AAV serotype 74 (AAVrh74) capsid proteins, wherein said recombinant hybrid AAV capsid protein has a reduced liver tropism compared to the parent AAV9 and AAVrh74 capsid proteins. The invention relates also to the derived hybrid AAV serotype vector particles packaging a gene of interest and their use in gene therapy, in particular for treating neuromuscular genetic diseases.
Type:
Grant
Filed:
April 4, 2019
Date of Patent:
July 16, 2024
Assignees:
Genethon, Institut National de la Sante et de la Recherche Medicale, Universite d'Evry val d'Essonne, Sorbonne Universite, Association Institut de Myologie
Abstract: An antibacterial agent suppresses the growth of gram-positive contaminating bacteria. The antibacterial agent is selected from: a lactylate in accordance with the general formula (R—(O—CH(CH3)—CO)aO)bM; a glycerol ester in accordance with the general formula CH2OR1—CHOR2—CH2OR3; and, mixtures thereof. In the general formulae: R represents a C4-C18 acyl group, R1, R2 and R3 are each independently selected from H or a C4-C18 acyl group, the acyl group having an alkyl or alkenyl chain which may be branched or unbranched, with the proviso that at least one of R1, R2 or R3 is H and at least one of R1, R2, or R3 is an acyl group; M represents a proton (H+) or a counter-cation chosen from the group Li, Na, K, Ca, Mg, Zn, Fe(II), Cu, Mn, Ag, ammonium or substituted ammonium having one or more (C1-4)alkyl optionally substituted with one or more hydroxyl.
Abstract: A method is provided for using hollow fibers having a porosity above 20 nm, in particular polyethersulfone hollow fibers, to impoverish blood and blood-derivatives from blood-derived extracellular vesicles, in particular exosomes and exomers. Methods for obtaining and analyzing the impoverished samples are also provided.
Type:
Grant
Filed:
March 29, 2019
Date of Patent:
July 9, 2024
Assignee:
Medica S.P.A.
Inventors:
Antonio Chiesi, Natasa Zarovni, Davide Zocco
Abstract: The present specification provides a semi-conducting biogenic hybrid catalyst capable of reducing CO2 into fuel precursors. Specifically, the present application involves a method for bio-assisted conversion of CO2 to fuel precursors using the semiconducting biogenic hybrid catalyst in a batch and a continuous mode.
Abstract: Provided is a stem cell filtrate preparation useful for hair regeneration, alleviation of pain caused by a disease of an interosseous joint, such as osteoarthrosis or rheumatoid arthritis, and treatment of the disease, and in addition, restoration of a damaged muscle, and prevention or treatment of decubitus. The stem cell filtrate preparation according to one aspect of the present invention is characterized by including a filtrate of a stem cell from which a cell membrane is removed. The stem cell may be at least one selected from at least one selected from an adipose-tissue-derived mesenchymal stem cell, an epithelial stem cell, a pigmented stem cell, an iPS cell, and an ES cell. Furthermore, the stem cell filtrate preparation includes an adipocyte or an effective component extracted from cellular fat.
Abstract: In the present invention, lymphocytes are efficiently grown by culturing lymphocytes in the presence of a novel recombinant fibronectin fragment.
Abstract: Provided are vaccines, polypeptides and polynucleotides based on mutant CALR and JAK2 sequences, vectors, host cells, viruses, and methods of making and using them. The disclosure also provides methods of inducing an immune response and methods of treating, preventing, reducing a risk of onset or delaying the onset of a clinical condition characterized by an expression of JAK2V617F or CALR exon 9 mutant, or both JAK2V617F and CALR exon 9 mutant, wherein the method comprises a plurality of administrations of any of the compositions comprising polynucleotides, polypeptides or vectors disclosed herein.
Type:
Grant
Filed:
November 13, 2020
Date of Patent:
June 25, 2024
Assignee:
Janssen Biotech, Inc.
Inventors:
Ricardo Attar, Jason Dehart, Selina Khan, Vinod Krishna, Jenifer Lum, Christian Maine, Barbara Sanders, Manuel Alejandro Sepulveda, Patrick Wilkinson, Roland Zahn
Abstract: Provided are methods and compositions for treating cancer in a subject in need thereof. One of the top gene products in glioblastoma multiforme (GBM) is KLRB1 (also known as CD161), a C-type lectin protein that binds to CLEC2D. Binding of CLEC2D to the KLRB1 receptor inhibits the cytotoxic function of NK cells as well as cytokine secretion. KLRB1 is only expressed by small subpopulations of human blood T cells, and consequently little is known about the function of this receptor in T cells. However, preliminary data demonstrate that KLRB1 expression is induced in T cells within the GBM microenvironment. In an exemplary embodiment, a method is provided comprising administering an agent capable of blocking the interaction of KLRB1 with its ligand. The agent may comprise an antibody or fragment thereof, which may bind KLRB1 or CLEC2D.
Type:
Grant
Filed:
November 13, 2018
Date of Patent:
June 25, 2024
Assignees:
The Broad Institute, Inc., Massachusetts Institute of Technology, The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
Inventors:
Mario Suva, Kai Wucherpfennig, Aviv Regev, Itay Tirosh, Nathan D. Mathewson
Abstract: The present disclosure provides for recombinant oncolytic viruses with gene deletions or insertions which result in downregulation of Major Histocompatibility Complex class I and alternatively or additively upregulation of Major Histocompatibility Complex class II. Immunologic and pharmaceutical compositions comprising these recombinant viruses and methods of using these compositions are also presented.
Abstract: The invention relates to the novel use of photosynthetic microorganisms to allow for the generation of micron-scale optical output mechanical sensors. In one preferred embodiment, the invention includes systems, methods and compositions for the use of photosynthetic microbes as biologically-based micron-scale tunable, light/chemical-mechanical energy transducers, sensors, and/or actuators.
Type:
Grant
Filed:
July 16, 2018
Date of Patent:
June 18, 2024
Assignee:
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Inventors:
Jeffrey Carlyle Cameron, Kristin A. Moore, Evan B. Johnson, Jian Wei Tay, Janet B. Fox, Sabina Altus, David Bortz
Abstract: Provided herein are methods for treating a disease or disorder associated with mitochondrial dysfunction through ex vivo introduction of a nucleic acid molecule into hematopoietic stem and progenitor cells (HSPCs) followed by transplantation of the HSPCs into a subject in need of treatment. The nucleic acid molecule may include a functional human frataxin (hFXN) or may include a gene editing system that when transfected into the cells removes a trinucleotide extension mutation of endogenous hFXN.
Type:
Grant
Filed:
March 16, 2020
Date of Patent:
June 18, 2024
Assignee:
The Regents of the University of California
Abstract: The present invention relates to a genetically modified hematopoietic stem cell comprising, in at least one globin gene comprised in the genome thereof, at least one transgene encoding a therapeutic protein or a therapeutic ribonucleic acid, the said transgene being placed under the control of the endogenous promoter of the said globin gene.
Type:
Grant
Filed:
January 11, 2019
Date of Patent:
June 18, 2024
Assignees:
Genethon, Institut National De La Sante Et De La Recherche Medicale
Abstract: Acellular amnion derived therapeutic compositions are described having a number of various compositional embodiments. An acellular amnion derived therapeutic composition has essentially no live or active amniotic cells. The amniotic cells may be destroyed and the cells and cell debris may be removed from the acellular amnion derived therapeutic composition. An acellular amnion derived therapeutic composition may comprise micronized placental tissue particles, and/or amniotic fluid. An acellular amnion derived therapeutic composition may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. An acellular amnion derived therapeutic composition may be combined with a matrix component to form a composite. An acellular amnion derived therapeutic composition may be used in conjunction with a composition comprising viable cells, such as stem cells.